| アブストラクト | PURPOSE: A post-authorization safety study program examined the cardiovascular safety of the long-acting muscarinic antagonist (LAMA) aclidinium bromide monotherapy and the LAMA/long-acting beta(2)-agonist (LABA) aclidinium bromide/formoterol fumarate. We assessed frequency and risk of any cardiac arrhythmias (CA), atrial fibrillation (AF), and serious ventricular arrhythmias (SVA) in aclidinium and aclidinium/formoterol users. PATIENTS AND METHODS: This population-based cohort study included adults with chronic obstructive pulmonary disease (COPD) initiating COPD medications in the UK Clinical Practice Research Datalink Aurum database (Jan 2015-Mar 2021). CA, AF, and SVA incidence rate ratios (IRR) were estimated using Poisson regression models for continuous current users initiating aclidinium and aclidinium/formoterol versus LABA, and during the first episode of current single use for aclidinium versus LAMA and aclidinium/formoterol versus LAMA/LABA, adjusting for clinically relevant covariables. RESULTS: The study included a total of 248,148 initiators. For CA and AF, respectively, adjusted IRRs (95% confidence intervals [CIs]) ranged from 0.98 (0.69-1.41) for LAMA/LABA to 2.08 (1.36-3.18) for aclidinium/formoterol and from 0.83 (0.55-1.24) for LAMA/LABA to 1.85 (1.15-3.00) for aclidinium/formoterol versus current LABA use. For current single use (first episode), adjusted IRRs (95% CIs) for CA and AF were 1.46 (0.93-2.29) and 1.57 (0.94-2.62) for aclidinium versus other LAMAs, and 2.15 (1.33-3.49) and 1.79 (0.96-3.33) for aclidinium/formoterol versus LAMA/LABA, respectively. There were few SVA events. CONCLUSION: CA and AF risks were increased for most study medications compared with LABA. Increased risks of CA and AF for several medications relative to LABA, LAMA, or LAMA/LABA may be driven by differences in baseline characteristics (eg, COPD severity). |
|---|
| ジャーナル名 | International journal of chronic obstructive pulmonary disease |
|---|
| Pubmed追加日 | 2026/3/23 |
|---|
| 投稿者 | Rebordosa, Cristina; Aguado, Jaume; Bartsch, Jennifer; Saigi-Morgui, Nuria; Carsin, Anne-Elie; Garcia-Esteban, Raquel; Ignatova, Elena; Freedman, Daniel; Perez-Gutthann, Susana; Rivero-Ferrer, Elena |
|---|
| 組織名 | RTI Health Solutions, Barcelona, Spain.;RTI Health Solutions, Research Triangle Park, NC, USA.;Covis Pharma Gmbh, a Wholly-Owned Subsidiary of Azurity Pharmaceuticals, Inc.,;Woburn, MA, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41868726/ |
|---|
